http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112472708-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 |
| filingDate | 2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112472708-B |
| titleOfInvention | Application of Eleutheroside E in the preparation of medicines for preventing and/or treating KOA |
| abstract | The present invention relates to a new application of Eleutheroside E, in particular to the application of Eleutheroside E in the preparation of medicines for preventing and/or treating knee osteoarthritis (KOA) and a pharmaceutical composition for treating knee osteoarthritis (KOA). The pharmaceutical composition for treating knee osteoarthritis can be made into injections, tablets, capsules, granules, drops, granules or ointments by adding common pharmaceutical auxiliary components to Eleutheroside E with a purity of more than 98%. The results of pharmacological experiments show that Eleutheroside E can significantly improve inflammatory cell infiltration, fibrous tissue hyperplasia, and cartilage surface destruction in osteoarthritis sites, and reduce the levels of MMP‑3, MMP‑9 and PGE 2 in serum. Eleutheroside E has a strong anti-inflammatory effect. Role in knee osteoarthritis (KOA). Therefore, Eleutheroside E can be used to prepare medicines for preventing and/or treating KOA. The invention provides a new drug source for the treatment of KOA. |
| priorityDate | 2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.